Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.49 |
| ▸ | JAK1 | P23458 | 11/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | TYK2 | P29597 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15389759 | 0.84 | AURKB (0.54) | JAK2JAK1JAK3TYK2CIT | |
| Trifluoroacetic Acid SCHEMBL15399201 | 0.82 | JAK2 (0.66) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL99002 | 0.81 | JAK2 (0.64) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL103973 | 0.80 | JAK2 (0.61) | JAK2HDAC6HDAC1JAK1JAK3 | |
| Trifluoroacetic Acid SCHEMBL101288 | 0.80 | JAK2 (0.61) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL101164 | 0.76 | JAK2 (0.58) | JAK2HDAC6JAK1JAK3TYK2 | |
| SCHEMBL15399202 | 0.76 | JAK2 (0.63) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL99729 | 0.76 | JAK2 (0.58) | JAK2HDAC6HDAC1JAK1JAK3 | |
| SCHEMBL99487 | 0.75 | JAK2 (0.60) | JAK2HDAC6JAK1JAK3TYK2 | |
| SCHEMBL19832101 | 0.75 | JAK2 (1.00) | JAK2HDAC6HDAC1JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184526-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | JAK2 4729/4885HDAC6 278/4885HDAC1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.